Impact of inhibitory KIR ligand mismatch and other variables on outcomes following myeloablative posttransplant cyclophosphamide-based T-cell-replete haploidentical bone marrow transplantation

Impact of inhibitory KIR ligand mismatch and other variables on outcomes following myeloablative posttransplant cyclophosphamide-based T-cell-replete haploidentical bone marrow transplantation

IntroductionPosttransplant cyclophosphamide (PTCy) has revolutionized the landscape of human leukocyte antigen (HLA)-haploidentical hematopoietic cell transplantation (haplo-HCT), providing a pivotal therapeutic option for patients with hematological malignancies who lack an HLA-matched donor.Method...

Full description

Saved in:
Bibliographic Details
Main Authors: Sarah Kayser, Emilia Salzmann-Manrique, Hubert Serve, Peter Bader, Jan-Henning Klusmann, Christian Seidl, Joachim Schwäble, Gesine Bug, Evelyn Ullrich
Format: Article
Language:English
Published: Frontiers Media S.A. 2024-12-01
Series:Frontiers in Immunology
Subjects:
hematopoietic cell transplantation (HCT)
T-cell-repleted haploidentical bone marrow transplantation (BMT)
posttransplant cyclophosphamide (PTCy)
hematological malignancies
inhibitory KIR ligand mismatch
recipient and donor variables
Online Access:https://www.frontiersin.org/articles/10.3389/fimmu.2024.1413927/full
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://www.frontiersin.org/articles/10.3389/fimmu.2024.1413927/full

Similar Items